The incidence of hyperglycemia increased in a dose-dependent manner following CYH33 administration, but was effectively managed by appropriate interventions, including dose interruption/reduction and concomitant oral antidiabetic medications, with or without insulin. Here, INS is linked to Hyperglycemia.